NCT06030895View on ClinicalTrials.gov

Sorafenib In Egyptian Patients With Hepatocellular Carcinoma.

NACompletedINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

December 12, 2022

Primary Completion Date

February 21, 2024

Study Completion Date

March 1, 2024

Conditions

Hepatocellular Carcinoma

Interventions

DRUG

Sorafenib Tablets

Sorafenib Tablets (200 -400 mg) twice daily

Trial Locations (1)

31527

Mansoura University Hospital, Al Mansurah

All Listed Sponsors

lead

Damanhour University

OTHER